Embleema
Embleema is a data and bioinformatics company specializing in precision medicine, integrating clinical, molecular, and real-world data using blockchain technology for secure clinical trials.
Services
Embleema offers a comprehensive data and bioinformatics platform aimed at enhancing precision medicine by integrating molecular, clinical, and real-world data. They provide an end-to-end data platform for personalized medicine, unifying different data types to support clinical decisions. Their services include the utilization of blockchain technology to enforce participant consents and ensure a full audit trail in clinical studies, providing transparency and security in data management.
HIVE Platform
Embleema provides the HIVE platform, a robust tool that has been operational since 2013 and is used by the FDA for regulatory decisions. The HIVE platform is authorized to operate (ATO) for analyzing genomic data in the FDA regulatory review environment. This platform plays a critical role in regulatory science, helping to facilitate the analysis and review of genomic data across various applications.
Partnerships
Embleema has partnered with organizations like CALYM to offer advanced clinical trial solutions for lymphoma research and development. They have also participated in partnerships to develop standards for cell and gene therapy patient monitoring with CDISC. Additionally, they received a multi-million dollar contract from the FDA to establish a reference database for genomic variants of COVID-19 and other microbial pathogens. These collaborations highlight Embleema's commitment to advancing research through strategic partnerships.
Innovations for Epilepsy
Embleema launched EDEN, a digital ecosystem designed specifically for epilepsy. EDEN connects patients, caregivers, providers, and researchers to streamline the management and research of epilepsy. This innovation provides a collaborative platform that facilitates better care and research outcomes for epilepsy, improving the quality of life for those affected by the condition.
Funding and Accelerator Program
Embleema closed a $3.7M Series A funding round, demonstrating significant investor confidence in their mission and technology. They also joined the Techstars Alchemist Blockchain Accelerator Program, which provides them with additional resources and mentorship to enhance their blockchain capabilities and accelerate their growth within the industry. These financial and strategic moves position Embleema for future expansion and technological advancements.